[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 28 of about 28
1. Ott K, Vogelsang H, Mueller J, Becker K, Müller M, Fink U, Siewert JR, Höfler H, Keller G: Chromosomal instability rather than p53 mutation is associated with response to neoadjuvant cisplatin-based chemotherapy in gastric carcinoma. Clin Cancer Res; 2003 Jun;9(6):2307-15
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chromosomal instability rather than p53 mutation is associated with response to neoadjuvant cisplatin-based chemotherapy in gastric carcinoma.
  • PURPOSE: The objective of the study was to evaluate microsatellite alterations [microsatellite instability (MSI) and loss of heterozygosity (LOH)] and mutation in the p53 gene in relation to response and patient survival to a cisplatin-based neoadjuvant chemotherapy in gastric cancer.
  • EXPERIMENTAL DESIGN: Fifty-three pretherapeutic gastric carcinoma biopsies were analyzed with 11 microsatellite markers.
  • Patients were treated with a cisplatin-based, neoadjuvant chemotherapy regimen.
  • Therapy response was evaluated by computed tomography scan, endoscopy, and endoluminal ultrasound.
  • With respect to LOH, LOH at chromosome 17p13 showed a significant association with therapy response (P = 0.022) but did not reach statistical significance in terms of patient survival.
  • The global LOH rate, expressed as fractional allelic loss (FAL), was assessed, and tumors were classified into tumors with a high (>0.5), medium (>0.25-0.5), and low (0-0.25) FAL value.
  • A statistically significant association of FAL with therapy response was found (P = 0.003), with a high FAL being related to therapy response.
  • CONCLUSIONS: A high level of chromosomal instability (high FAL value) defines a subset of patients who are more likely to benefit from cisplatin-based neoadjuvant chemotherapy. p53 mutation status is not significantly associated with therapy response and is not a useful marker for response prediction.
  • [MeSH-major] Chromosomal Instability. Genes, p53. Mutation. Stomach Neoplasms / drug therapy. Stomach Neoplasms / genetics
  • [MeSH-minor] Adult. Aged. Alleles. Chemotherapy, Adjuvant. Cisplatin / therapeutic use. Female. Humans. Immunohistochemistry. Loss of Heterozygosity. Male. Microsatellite Repeats. Middle Aged. Tumor Suppressor Protein p53 / analysis

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12796400.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Tumor Suppressor Protein p53; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


2. Otto C, Kaemmerer U, Illert B, Muehling B, Pfetzer N, Wittig R, Voelker HU, Thiede A, Coy JF: Growth of human gastric cancer cells in nude mice is delayed by a ketogenic diet supplemented with omega-3 fatty acids and medium-chain triglycerides. BMC Cancer; 2008;8:122
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Growth of human gastric cancer cells in nude mice is delayed by a ketogenic diet supplemented with omega-3 fatty acids and medium-chain triglycerides.
  • This phenomenon, known as aerobic glycolysis or the Warburg effect, may provide a rationale for therapeutic strategies that inhibit tumour growth by administration of a ketogenic diet with average protein but low in carbohydrates and high in fat enriched with omega-3 fatty acids and medium-chain triglycerides (MCT).
  • METHODS: Twenty-four female NMRI nude mice were injected subcutaneously with tumour cells of the gastric adenocarcinoma cell line 23132/87.
  • Experiments were ended upon attainment of the target tumor volume of 600 mm3 to 700 mm3.
  • The two diets were compared based on tumour growth and survival time (interval between tumour cell injection and attainment of target tumour volume).
  • [MeSH-major] Adenocarcinoma / diet therapy. Diet, Carbohydrate-Restricted. Fatty Acids, Omega-3 / administration & dosage. Stomach Neoplasms / diet therapy. Triglycerides / administration & dosage
  • [MeSH-minor] 3-Hydroxybutyric Acid. Animals. Biomarkers, Tumor / biosynthesis. Cell Line, Tumor. Female. Humans. Mice. Mice, Nude. Neoplasm Transplantation. Neovascularization, Pathologic / diet therapy. Tumor Burden / drug effects

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur Surg Res. 1994;26(5):288-97 [7835386.001]
  • [Cites] Exp Cell Res. 2002 May 15;276(1):24-31 [11978005.001]
  • [Cites] J Am Coll Nutr. 1995 Apr;14(2):202-8 [7790697.001]
  • [Cites] Cancer. 1998 Jan 15;82(2):395-402 [9445198.001]
  • [Cites] Cancer Detect Prev. 1998;22(3):219-24 [9618043.001]
  • [Cites] J Cell Physiol. 1998 Aug;176(2):342-9 [9648921.001]
  • [Cites] J Natl Cancer Inst. 1999 Mar 17;91(6):512-23 [10088621.001]
  • [Cites] Br J Cancer. 1999 Sep;81(1):80-6 [10487616.001]
  • [Cites] Nat Rev Cancer. 2004 Nov;4(11):891-9 [15516961.001]
  • [Cites] Cancer Res. 2005 Jan 15;65(2):613-21 [15695406.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Apr 26;102(17):5992-7 [15840712.001]
  • [Cites] Curr Oncol Rep. 2005 Jul;7(4):271-6 [15946586.001]
  • [Cites] Clin Lab. 2005;51(5-6):257-73 [15991799.001]
  • [Cites] J Biochem Biophys Methods. 2005 Sep 30;64(3):207-15 [16182371.001]
  • [Cites] JAMA. 2006 Jan 25;295(4):403-15 [16434631.001]
  • [Cites] Br J Cancer. 2006 Feb 27;94(4):578-85 [16465194.001]
  • [Cites] BMJ. 2006 Apr 1;332(7544):752-60 [16565093.001]
  • [Cites] Oncogene. 2006 Aug 7;25(34):4633-46 [16892078.001]
  • [Cites] Int J Cancer. 2006 Dec 15;119(12):2733-41 [17019714.001]
  • [Cites] J Cell Sci. 2007 Feb 1;120(Pt 3):379-83 [17251378.001]
  • [Cites] Int J Gynecol Cancer. 2007 Jan-Feb;17(1):101-6 [17291239.001]
  • [Cites] J Biol Chem. 2002 Jun 28;277(26):23111-5 [11943784.001]
  • [Cites] J Nutr. 2002 Jul;132(7):1879-85 [12097663.001]
  • [Cites] Cancer Lett. 2002 Nov 8;185(1):31-7 [12142076.001]
  • [Cites] Nat Rev Cancer. 2002 Nov;2(11):862-71 [12415256.001]
  • [Cites] J Nutr. 2002 Nov;132(11 Suppl):3508S-3512S [12421878.001]
  • [Cites] J Biol Chem. 2003 Sep 26;278(39):37832-9 [12853461.001]
  • [Cites] Br J Cancer. 2003 Oct 6;89(7):1375-82 [14520474.001]
  • [Cites] Clin Exp Metastasis. 2003;20(6):549-54 [14598889.001]
  • [Cites] Prostaglandins Leukot Essent Fatty Acids. 2004 Mar;70(3):309-19 [14769489.001]
  • [Cites] Cancer Res. 2004 Jun 1;64(11):3892-9 [15172999.001]
  • [Cites] Br J Cancer. 1985 Jul;52(1):87-92 [2861842.001]
  • [Cites] Br J Cancer. 1989 May;59(5):677-81 [2736199.001]
  • [Cites] Lipids. 1991 Apr;26(4):271-6 [1714032.001]
  • [Cites] Virchows Arch B Cell Pathol Incl Mol Pathol. 1993;63(6):335-43 [8100658.001]
  • [Cites] J Natl Cancer Inst. 1993 Nov 3;85(21):1743-7 [8411258.001]
  • [Cites] Pediatrics. 2007 Mar;119(3):535-43 [17332207.001]
  • [Cites] Nat Protoc. 2007;2(2):247-50 [17406581.001]
  • [Cites] Blood. 2007 May 1;109(9):3812-9 [17255361.001]
  • [Cites] Am J Physiol Endocrinol Metab. 2007 Jun;292(6):E1724-39 [17299079.001]
  • [Cites] Nutr Cancer. 2007;57(2):177-83 [17571951.001]
  • [Cites] J Clin Invest. 2007 Jul;117(7):1866-75 [17607361.001]
  • [Cites] Nat Med. 2007 Jul;13(7):868-73 [17589522.001]
  • [Cites] Eur Arch Otorhinolaryngol. 2007 Dec;264(12):1431-6 [17639446.001]
  • [Cites] Int J Cancer. 2008 Jun 1;122(11):2422-8 [18302154.001]
  • [Cites] Cell. 2000 Jan 7;100(1):57-70 [10647931.001]
  • [Cites] Cancer Res. 2000 Feb 15;60(4):916-21 [10706105.001]
  • [Cites] J Am Diet Assoc. 1995 Jun;95(6):693-7 [7759747.001]
  • (PMID = 18447912.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Fatty Acids, Omega-3; 0 / Triglycerides; TZP1275679 / 3-Hydroxybutyric Acid
  • [Other-IDs] NLM/ PMC2408928
  •  go-up   go-down


3. Chen B, Cao S, Zhang Y, Wang X, Liu J, Hui X, Wan Y, Du W, Wang L, Wu K, Fan D: A novel peptide (GX1) homing to gastric cancer vasculature inhibits angiogenesis and cooperates with TNF alpha in anti-tumor therapy. BMC Cell Biol; 2009;10:63
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A novel peptide (GX1) homing to gastric cancer vasculature inhibits angiogenesis and cooperates with TNF alpha in anti-tumor therapy.
  • BACKGROUND: The discovery of the importance of angiogenesis in tumor growth has emphasized the need to find specific vascular targets for tumor-targeted therapies.
  • Previously, using phage display technology, we identified the peptide GX1 as having the ability to target the gastric cancer vasculature.
  • The present study investigated the bioactivities of GX1, as well as its potential ability to cooperate with recombinant mutant human tumor necrosis factor alpha (rmhTNFalpha), in gastric cancer therapy.
  • RESULTS: Tetrazolium salt (MTT) assay showed that GX1 could inhibit cell proliferation of both human umbilical vein endothelial cells (HUVEC) (44%) and HUVEC with tumor endothelium characteristics, generated by culturing in tumor-conditioned medium (co-HUVEC) (62%).
  • When GX1 was fused to rmhTNFalpha, GX1-rmhTNFalpha selectively concentrated in the gastric cancer vasculature, as shown by enzyme-linked immunosorbent assay, immunofluorescence and emission-computed tomography.
  • In a tumor formation test, GX1-rmhTNFalpha more effectively inhibited tumor growth than rmhTNFalpha (tumor volume: 271 mm3 vs. 134 mm3, p < 0.05), with less systemic toxicity as measured by body weight (20.57 g vs. 19.30 g, p < 0.05).
  • These therapeutic effects may be mediated by selectively enhanced tumor vascular permeability, as indicated by Evan's blue assay.
  • Furthermore, when GX1 was conjugated to rmhTNFalpha, the fusion protein was selectively delivered to targeted tumor sites, significantly improving the anti-tumor activity of rmhTNFalpha and decreasing systemic toxicity.
  • These results demonstrate the potential of GX1 as a homing peptide in vascular targeted therapy for gastric cancer.
  • [MeSH-major] Angiogenesis Inhibitors / therapeutic use. Antineoplastic Agents / therapeutic use. Oligopeptides / therapeutic use. Stomach Neoplasms / blood supply. Stomach Neoplasms / drug therapy. Tumor Necrosis Factor-alpha / therapeutic use
  • [MeSH-minor] Animals. Apoptosis / drug effects. Cells, Cultured. Disease Progression. Endothelial Cells / cytology. Endothelial Cells / drug effects. Humans. Mice. Mice, Nude. Peptides, Cyclic

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Science. 2000 Aug 18;289(5482):1197-202 [10947988.001]
  • [Cites] J Control Release. 2008 Oct 21;131(2):86-93 [18700158.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 May 28;99(11):7444-9 [12032302.001]
  • [Cites] Nat Rev Cancer. 2002 Oct;2(10):750-63 [12360278.001]
  • [Cites] J Cell Sci. 2003 Mar 15;116(Pt 6):1013-22 [12584245.001]
  • [Cites] Biotechnol Appl Biochem. 2003 Apr;37(Pt 2):109-13 [12630898.001]
  • [Cites] Semin Cancer Biol. 2003 Apr;13(2):159-67 [12654259.001]
  • [Cites] Clin Cancer Res. 2003 Dec 15;9(17):6371-80 [14695137.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Jun 22;101(25):9381-6 [15197262.001]
  • [Cites] N Engl J Med. 1971 Nov 18;285(21):1182-6 [4938153.001]
  • [Cites] Gene. 1980 Apr;9(1-2):127-40 [6247241.001]
  • [Cites] J Cell Biol. 1988 Mar;106(3):925-30 [2450101.001]
  • [Cites] Cancer Metastasis Rev. 1990 Nov;9(3):267-82 [2292139.001]
  • [Cites] Br J Cancer. 1992 Nov;66(5):794-9 [1419622.001]
  • [Cites] Curr Opin Oncol. 1992 Dec;4(6):1142-8 [1457528.001]
  • [Cites] J Cell Biochem. 1994 Sep;56(1):52-61 [7806592.001]
  • [Cites] Nat Biotechnol. 1997 Jun;15(6):542-6 [9181576.001]
  • [Cites] Methods Mol Biol. 1998;80:347-54 [9664392.001]
  • [Cites] J Clin Invest. 1999 May;103(9):1227-30 [10225964.001]
  • [Cites] Cancer Biol Ther. 2004 Dec;3(12):1232-5 [15492500.001]
  • [Cites] Protein Expr Purif. 2006 Jan;45(1):60-5 [16027006.001]
  • [Cites] Trends Cardiovasc Med. 2006 Apr;16(3):80-8 [16546688.001]
  • [Cites] Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi. 2006 May;22(3):360-2 [16643800.001]
  • [Cites] Cancer. 2006 Sep 15;107(6):1207-18 [16909423.001]
  • [Cites] Clin Cancer Res. 2007 Feb 1;13(3):816-23 [17289872.001]
  • [Cites] Drugs. 2008;68(3):299-317 [18257608.001]
  • [Cites] J Nucl Med. 2008 Jun;49 Suppl 2:113S-28S [18523069.001]
  • [Cites] Nat Rev Cancer. 2008 Aug;8(8):579-91 [18596824.001]
  • [Cites] Cancer Cell. 2008 Sep 9;14(3):263-73 [18772115.001]
  • [Cites] Blood. 2008 Oct 1;112(7):2628-35 [18574027.001]
  • [Cites] Cancer. 2008 Oct 1;113(7 Suppl):1857-87 [18798529.001]
  • [Cites] Curr Opin Mol Ther. 2008 Oct;10(5):428-30 [18830917.001]
  • [Cites] Nat Med. 2002 Feb;8(2):121-7 [11821895.001]
  • (PMID = 19740430.001).
  • [ISSN] 1471-2121
  • [Journal-full-title] BMC cell biology
  • [ISO-abbreviation] BMC Cell Biol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Antineoplastic Agents; 0 / Oligopeptides; 0 / Peptides, Cyclic; 0 / Tumor Necrosis Factor-alpha; 0 / cyclo(cysteinyl-glycyl-aspargyl-seryl-aspargyl-prolyl-lysyl-seryl-cysteine)
  • [Other-IDs] NLM/ PMC2746182
  •  go-up   go-down


Advertisement
4. Urbańczyk K, Stachura J, Papla B, Karcz D, Matłok M: Gastric solid glomus tumor and multiple glomangiomyomas of the large bowel with intravascular spread, multifocal perivascular proliferations and liver involvement. Pol J Pathol; 2007;58(3):207-14
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gastric solid glomus tumor and multiple glomangiomyomas of the large bowel with intravascular spread, multifocal perivascular proliferations and liver involvement.
  • The authors present a case of multiple glomus tumors (GTs) of the gastrointestinal tract, representing the type of a gastric glomus tumor proper and large bowel glomangiomyomas with myopericytoma-like features, observed in a 46-year old female, with multifocal perivascular proliferations of primitive cells and hepatic involvement.
  • Histologically, the multilobular gastric tumor and hepatic lesions corresponded to a typical glomus tumor, while the tumor situated in the transverse colon, up to 7 cm in diameter, presented as a glomangiomyoma infiltrative (with myopericytoma-like foci), and satellite tumors in the large bowel mucosa, 0.5-0.7 cm in diameter, represented small glomangiomyomas.
  • In addition, the patient demonstrated two types of concomitant vascular lesions: 1/ intravascular spread in the form of neoplastic plugs that obliterated the lumen of medium-size veins, and 2/ microscopic perivascular proliferation of primitive, small cells seen in the vicinity of the main tumor and in the adjacent adipose tissue.
  • The patient has been ill for 2.5 years; she has been subjected to a partial colectomy with a resection of the small intestinal loop, greater omentum and the right ovary, followed by chemotherapy.
  • It seems that at present, the group of perivascular SMA+ tumors may include infantile-type myofibromatosis in adults, myopericytoma, glomangio(myo)pericytoma, glomangiomyoma, glomus tumor proper, and glomangioma.
  • In the remaining cases, determination whether the patient has metastatic disease requires deep consideration and caution, also while deciding on treatment to be employed.
  • [MeSH-major] Glomus Tumor / secondary. Intestine, Large / pathology. Liver Neoplasms / secondary. Neoplasms, Multiple Primary / pathology. Stomach Neoplasms / pathology
  • [MeSH-minor] Biomarkers, Tumor / analysis. Female. Humans. Immunohistochemistry. Middle Aged

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18074867.001).
  • [ISSN] 1233-9687
  • [Journal-full-title] Polish journal of pathology : official journal of the Polish Society of Pathologists
  • [ISO-abbreviation] Pol J Pathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


5. Shao QS, Ye ZY, Ling ZQ, Ke JJ: Cell cycle arrest and apoptotic cell death in cultured human gastric carcinoma cells mediated by arsenic trioxide. World J Gastroenterol; 2005 Jun 14;11(22):3451-6
Hazardous Substances Data Bank. ARSENIC TRIOXIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cell cycle arrest and apoptotic cell death in cultured human gastric carcinoma cells mediated by arsenic trioxide.
  • AIM: To investigate the effect of arsenic trioxide on human gastric cancer cell line MKN45 with respect to both cytotoxicity and induction of apoptosis in vitro.
  • The inhibitory rate of colony-formation was 38.5%, 99.1%, and 99.5% when the concentration of As2O3 was 1, 5, and 10 micromol/L in culture medium, respectively.
  • The cell number of a single colony in drug treatment groups was less than that of control group.
  • The cell-killing rate of As2O3 to MKN45 cells was both dose- and time-dependent with an IC50 of (11.05+/-0.25) micromol/L.
  • The results showed that As2O3 induced time- and dose-dependent apoptosis in MKN45 cells, blocked at G2/M phase.
  • The apoptotic peak (sub-G1 phase) appeared and cell apoptotic rate in MKN45 cells was 18.3-32.5% after treatment by 10 micromol/L As2O3 for 48 h.
  • The percentage of G2/M cell of the experimental groups was 2.0-5.0 times than that of the control group.
  • CONCLUSION: As2O3 can induce apoptosis of human gastric carcinoma cells MKN45, which is the basis of its effectiveness.
  • It shows great potential in the treatment of gastric carcinoma.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Agents / pharmacology. Apoptosis / drug effects. Arsenicals / pharmacology. Oxides / pharmacology. Stomach Neoplasms / drug therapy
  • [MeSH-minor] Cell Cycle / drug effects. Cell Line, Tumor. Humans

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15948253.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Arsenicals; 0 / Oxides; S7V92P67HO / arsenic trioxide
  • [Other-IDs] NLM/ PMC4316002
  •  go-up   go-down


6. Sawai M, Yashiro M, Nishiguchi Y, Ohira M, Hirakawa K: Growth-inhibitory effects of the ketone body, monoacetoacetin, on human gastric cancer cells with succinyl-CoA: 3-oxoacid CoA-transferase (SCOT) deficiency. Anticancer Res; 2004 Jul-Aug;24(4):2213-7
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Growth-inhibitory effects of the ketone body, monoacetoacetin, on human gastric cancer cells with succinyl-CoA: 3-oxoacid CoA-transferase (SCOT) deficiency.
  • In this study, the effect of MAA on the growth of human gastric cancer cells was examined in relation to SCOT expression.
  • MATERIALS AND METHODS: Four gastric cancer cell lines, OCUM-2M, MKN-28, MKN-45 and MKN-74, and two fibroblast cell lines were used in this study.
  • The proliferation of gastric cancer cells was determined by MTT assay, by calculating the number of cancer cells, and by [3H]-thymidine uptake.
  • RESULTS: The growth of OCUM-2M and MKN-28 cells was significantly suppressed in MAA medium compared with glucose medium.
  • In contrast the growth of MKN-74, MKN-45 and normal fibroblasts was not suppressed in MAA medium.
  • CONCLUSION: Parenteral nutrition with MAA may provide preferential energy for patients with some types of gastric cancer with SCOT deficiency.
  • [MeSH-major] Acetoacetates / pharmacology. Coenzyme A-Transferases / deficiency. Glycerides / pharmacology. Stomach Neoplasms / drug therapy. Stomach Neoplasms / enzymology
  • [MeSH-minor] Cell Division / drug effects. Cell Line, Tumor. Growth Inhibitors / pharmacology. Humans. RNA, Messenger / biosynthesis. RNA, Messenger / genetics. Reverse Transcriptase Polymerase Chain Reaction

  • Genetic Alliance. consumer health - SCOT deficiency.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15330163.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Acetoacetates; 0 / Glycerides; 0 / Growth Inhibitors; 0 / RNA, Messenger; 66523-11-3 / monoacetoacetin; EC 2.8.3.- / Coenzyme A-Transferases; EC 2.8.3.5 / 3-ketoacid CoA-transferase
  •  go-up   go-down


7. Zhu BH, Zhan WH, Li ZR, Wang Z, He YL, Peng JS, Cai SR, Ma JP, Zhang CH: (-)-Epigallocatechin-3-gallate inhibits growth of gastric cancer by reducing VEGF production and angiogenesis. World J Gastroenterol; 2007 Feb 28;13(8):1162-9
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] (-)-Epigallocatechin-3-gallate inhibits growth of gastric cancer by reducing VEGF production and angiogenesis.
  • AIM: To investigate the effect of (-)-epigallocatechin-3-gallate (EGCG) on growth of gastric cancer and its possible mechanism.
  • Tumor growth was measured by calipers in two dimensions.
  • Tumor angiogenesis was determined with tumor microvessel density (MVD) by immunohistology.
  • VEGF mRNA expression was determined by RT-PCR and VEGF release in tumor culture medium by ELISA.
  • RESULTS: Intraperitoneal injection of EGCG inhibited the growth of gastric cancer by 60.4%.
  • MVD in tumor tissues treated with EGCG was markedly reduced.
  • EGCG treatment reduced VEGF protein level in vitro and in vivo.
  • Secretion and mRNA expression of VEGF in tumor cells were also suppressed by EGCG in a dose-dependent manner.
  • This inhibitory effect was associated with reduced activation of Stat3, but EGCG treatment did not change the total Stat3 expression.
  • CONCLUSION: EGCG inhibits the growth of gastric cancer by reducing VEGF production and angiogenesis, and is a promising candidate for anti-angiogenic treatment of gastric cancer.
  • [MeSH-major] Anticarcinogenic Agents / therapeutic use. Carcinoma / drug therapy. Catechin / analogs & derivatives. Neovascularization, Pathologic / drug therapy. Stomach Neoplasms / drug therapy. Vascular Endothelial Growth Factor A / drug effects
  • [MeSH-minor] Animals. Cell Line, Tumor. Cell Movement / drug effects. Cell Proliferation / drug effects. Endothelial Cells / drug effects. Female. Gene Expression Regulation, Neoplastic. Humans. Mice. Mice, Inbred BALB C. Mice, Nude. STAT3 Transcription Factor / drug effects. Xenograft Model Antitumor Assays

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Life Sci. 2003 Jul 25;73(10):1299-313 [12850245.001]
  • [Cites] Mutat Res. 2003 Feb-Mar;523-524:201-8 [12628518.001]
  • [Cites] Front Biosci. 2004 Sep 1;9:2618-31 [15358585.001]
  • [Cites] Cytokine Growth Factor Rev. 2004 Oct;15(5):297-324 [15450248.001]
  • [Cites] Jpn J Cancer Res. 1988 Oct;79(10):1067-74 [3143695.001]
  • [Cites] N Engl J Med. 1991 Jan 3;324(1):1-8 [1701519.001]
  • [Cites] Jpn J Cancer Res. 1996 Sep;87(9):958-62 [8878459.001]
  • [Cites] Cancer Res. 1997 Oct 1;57(19):4414-9 [9331105.001]
  • [Cites] Cancer Lett. 1998 Jul 17;129(2):173-9 [9719459.001]
  • [Cites] Nature. 1999 Apr 1;398(6726):381 [10201368.001]
  • [Cites] Clin Cancer Res. 2005 Feb 15;11(4):1386-93 [15746037.001]
  • [Cites] Biol Pharm Bull. 2005 Apr;28(4):574-9 [15802789.001]
  • [Cites] J Epidemiol. 2005 Jun;15 Suppl 2:S109-12 [16127221.001]
  • [Cites] World J Gastroenterol. 2006 Jan 7;12(1):17-20 [16440411.001]
  • [Cites] Int J Cancer. 2006 Apr 1;118(7):1635-44 [16217757.001]
  • [Cites] Mol Carcinog. 2006 Jun;45(6):431-5 [16652355.001]
  • [Cites] Int J Cancer. 1993 Jun 19;54(4):594-606 [8514451.001]
  • [Cites] Cancer Res. 1995 May 15;55(10):2081-4 [7743506.001]
  • [Cites] Br J Cancer. 2001 Mar 23;84(6):844-50 [11259102.001]
  • [Cites] Cancer Res. 2002 Jan 15;62(2):381-5 [11809684.001]
  • [Cites] Int J Exp Pathol. 2001 Dec;82(6):309-16 [11846837.001]
  • [Cites] Oncogene. 2002 Mar 27;21(13):2000-8 [11960372.001]
  • [Cites] J Exp Clin Cancer Res. 2002 Mar;21(1):125-9 [12071518.001]
  • [Cites] J Nutr. 2002 Aug;132(8):2307-11 [12163680.001]
  • [Cites] Cancer Lett. 2002 Jun 28;180(2):139-44 [12175544.001]
  • [Cites] J Exp Ther Oncol. 2002 Nov-Dec;2(6):350-9 [12440226.001]
  • [Cites] J Clin Epidemiol. 2003 Jan;56(1):1-9 [12589864.001]
  • [Cites] Cancer. 2003 Mar 15;97(6):1442-6 [12627508.001]
  • [Cites] Int J Cancer. 2003 Oct 10;106(6):871-8 [12918064.001]
  • (PMID = 17451194.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Anticarcinogenic Agents; 0 / STAT3 Transcription Factor; 0 / Vascular Endothelial Growth Factor A; 8R1V1STN48 / Catechin; BQM438CTEL / epigallocatechin gallate
  • [Other-IDs] NLM/ PMC4146988
  •  go-up   go-down


8. Giatromanolaki A, Stathopoulos GP, Koukourakis MI, Rigatos S, Vrettou E, Kittas C, Fountzilas G, Sivridis E: Angiogenesis and apoptosis-related protein (p53, bcl-2, and bax) expression versus response of gastric adenocarcinomas to paclitaxel and carboplatin chemotherapy. Am J Clin Oncol; 2001 Jun;24(3):222-6
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Angiogenesis and apoptosis-related protein (p53, bcl-2, and bax) expression versus response of gastric adenocarcinomas to paclitaxel and carboplatin chemotherapy.
  • The role of angiogenesis and apoptosis-related proteins in defining response to chemotherapy is poorly understood.
  • We examined the microvessel density (MVD) and the expression of p53, bcl-2, and bax proteins in a series of 28 locally advanced gastric adenocarcinomas, treated with paclitaxel and carboplatin.
  • Microvessel density was assigned in three categories: low (<35), medium (35-60), and high (>60).
  • Tumors of medium MVD showed a significantly higher response rate compared with those of high or low MVD (p = 0.01 and 0.001, respectively), and prognosis was significantly better in this group of patients with medium MVD tumors (p < 0.02).
  • Loss of bax protein expression was somewhat more frequent in tumors resistant to chemotherapy, but this difference was not of statistical significance.
  • The expression of p53 and bcl-2 did not influence the outcome of treatment.
  • The present study suggests that although apoptosis-related proteins may have a role in defining response to taxanes, parameters related to tumors' vasculature, such as drug availability or angiogenic tissue regeneration, may be equally important.
  • [MeSH-major] Adenocarcinoma / drug therapy. Adenocarcinoma / metabolism. Antineoplastic Agents / therapeutic use. Carboplatin / therapeutic use. Paclitaxel / therapeutic use. Proto-Oncogene Proteins / biosynthesis. Proto-Oncogene Proteins c-bcl-2 / biosynthesis. Stomach Neoplasms / drug therapy. Stomach Neoplasms / metabolism. Tumor Suppressor Protein p53 / biosynthesis

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11404489.001).
  • [ISSN] 0277-3732
  • [Journal-full-title] American journal of clinical oncology
  • [ISO-abbreviation] Am. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / BAX protein, human; 0 / Proto-Oncogene Proteins; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / Tumor Suppressor Protein p53; 0 / bcl-2-Associated X Protein; BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


9. Lee H, Lee JH, Jung KH, Hong SS: Deguelin promotes apoptosis and inhibits angiogenesis of gastric cancer. Oncol Rep; 2010 Oct;24(4):957-63
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Deguelin promotes apoptosis and inhibits angiogenesis of gastric cancer.
  • Gastric cancer is often diagnosed in locally advanced or metastatic stages, which preludes a poor prognosis.
  • As only 10% of patients with advanced gastric cancer treated with chemotherapy survive 2 years, new approaches for preventing and controlling the disease are required.
  • We therefore, assessed in gastric cancer cells the chemotherapeutic potential and mechanism of deguelin, a rotenoid of the flavonoid family isolated from several plant species.
  • The effect of deguelin on the proliferation and apoptosis in the gastric cancer cells were assessed by MTT and flow cytometry.
  • The growth of gastric cancer cells (SNU-484, AGS and MKN-28) was inhibited by deguelin in a dose-dependent manner.
  • G2/M phase arrest was induced by deguelin in gastric cancer cells. deguelin (1 microM) induced chromatin condensation and DNA fragmentation.
  • Also the exposure to 1 microM deguelin resulted in the increase in early-apoptotic cells (Annexin V-positive/Propidium iodide-negative) after 24 h, compared to the cells in the control medium (31 versus 12%).
  • Deguelin-induced apoptosis involved the caspase-9 and caspase-3 pathways in gastric cancer cells.
  • Akt phosphorylation, hypoxia-inducible factor-1alpha accumulation, and vascular endothelial growth factor expression in gastric cancer cells was inhibited by deguelin.
  • Taken together, deguelin showed anticancer activity in gastric cancer cells, which is correlated with the inhibition of angiogenesis and induction of apoptosis.
  • Deguelin may be a potential agent in inhibiting the progression of gastric cancer by virtue of its activity on these crucial cell characteristics.
  • [MeSH-major] Antineoplastic Agents / pharmacology. Apoptosis / drug effects. Neovascularization, Pathologic / drug therapy. Rotenone / analogs & derivatives. Stomach Neoplasms / drug therapy
  • [MeSH-minor] Blotting, Western. Cell Line, Tumor. Cell Proliferation / drug effects. Cell Separation. Flow Cytometry. Humans. In Situ Nick-End Labeling. Reverse Transcriptase Polymerase Chain Reaction

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. ROTENONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20811676.001).
  • [ISSN] 1791-2431
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 03L9OT429T / Rotenone; K5Z93K66IE / deguelin
  •  go-up   go-down


10. Takada J, Kenno S, Aoki T, Hamada H, Katsuki Y: [A case in which intra-arterial chemotherapy for simultaneous hepatic metastases markedly improved AFP-producing gastric cancer]. Gan To Kagaku Ryoho; 2009 Nov;36(12):2326-9
Hazardous Substances Data Bank. EPIRUBICIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case in which intra-arterial chemotherapy for simultaneous hepatic metastases markedly improved AFP-producing gastric cancer].
  • The prognosis of most hepatic and lymph node metastases in AFP-producing gastric cancer is poor, and despite the use of multimodal therapy, the average survival period is reported to be approximately one year.
  • Described here is one example in which intra-arterial chemotherapy for simultaneous hepatic metastases in AFP-producing gastric cancer achieved a marked improvement.
  • Distal gastrectomy was performed for Type II gastric cancer.
  • L, type 2, 5.5x2.4 cm, tub 2>por 1, pT2 (MP), int, INF b, ly2, v1, pN1, pPM (-), pDM (-), pH1: stage IV.
  • The AFP level before surgery was 801.4 ng/mL and lowered to 65.8 ng/mL after surgery, AFP-producing gastric cancer and simultaneous hepatic metastases (S4, single lesion) was diagnosed based upon imaging examinations.
  • 5-FU+epirubicin+MMC (FEM)intra-arterial chemotherapy was started one month following surgery, but because CT showed multiple new hepatic lesions(S4, S5)four months following surgery, DSM therapy was performed with hepatic arterial injections of MMC 10 mg, DSM 300 mg.
  • Dynamic CT showed a reduction in size of the tumors in both S4 and S5, and at five months following surgery, hepatic arterial infusion chemotherapy FP (CDDP 5 mg+5-FU 250 mg weekly) was started and performed 45 times in a 14-month period.
  • During therapy, CR was achieved for the hepatic metastases and tumor marker levels were also normal.
  • Because an introduction of contrast medium into the hepatic reservoir showed a narrowing of the hepatic artery and inflow of contrast medium into the splenic artery, arterial infusion was terminated.
  • This suggests the possibility that intra-arterial chemotherapy is an effective treatment method for hepatic metastases in AFP-producing gastric cancer.
  • [MeSH-major] Adenocarcinoma / drug therapy. Adenocarcinoma / pathology. Liver Neoplasms / drug therapy. Liver Neoplasms / secondary. Stomach Neoplasms / pathology. alpha-Fetoproteins / biosynthesis
  • [MeSH-minor] Aged. Antibiotics, Antineoplastic / administration & dosage. Antimetabolites, Antineoplastic / administration & dosage. Antineoplastic Agents / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Cisplatin / administration & dosage. Epirubicin / administration & dosage. Female. Fluorouracil / administration & dosage. Gastrectomy. Hepatic Artery. Humans. Infusions, Intra-Arterial. Mitomycin / administration & dosage

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. MITOMYCIN C .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20037411.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / Antimetabolites, Antineoplastic; 0 / Antineoplastic Agents; 0 / alpha-Fetoproteins; 3Z8479ZZ5X / Epirubicin; 50SG953SK6 / Mitomycin; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


11. Chan MW, Wong CY, Cheng AS, Chan VY, Chan KK, To KF, Chan FK, Sung JJ, Leung WK: Targeted inhibition of COX-2 expression by RNA interference suppresses tumor growth and potentiates chemosensitivity to cisplatin in human gastric cancer cells. Oncol Rep; 2007 Dec;18(6):1557-62
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Targeted inhibition of COX-2 expression by RNA interference suppresses tumor growth and potentiates chemosensitivity to cisplatin in human gastric cancer cells.
  • Although selective cyclooxygenase-2 (COX-2) inhibitors suppress cell proliferation in gastric cancer, it remains debatable whether their effect is mediated through COX-2 dependent or independent pathways.
  • We investigated the effects of the targeted inhibition of COX-2 expression by small interfering RNA (siRNA) in human gastric cancer cells and compared it to the effects of treatment with a specific COX-2 inhibitor.
  • COX-2 mRNA and proteins were significantly reduced by up to 80% on day 2 after COX-2 siRNA transfection to the gastric cancer cell line MKN45.
  • Concentrations of prostaglandins E2 (PGE2) in the condition medium were also reduced to 30% after siRNA transfection.
  • Transfection of COX-2 siRNA exhibited a more potent anti-proliferative effect on MKN45 cells than treatment with high-dose (100 microM) NS398.
  • COX-2 siRNA also significantly reduced tumor growth in nude mice.
  • While COX-2 siRNA transfection alone had no obvious pro-apoptotic effects, unlike low-dose (10 microM) NS398 it enhanced the apoptotic reaction of MKN45 cells to cisplatin therapy.
  • In conclusion, our results demonstrate for the first time that COX-2 siRNA inhibits cell growth and enhances the chemosensitivity of gastric cancer cells.
  • RNA interference may be a promising alternative to specific COX-2 inhibitors in the prevention and treatment of gastric cancer.
  • [MeSH-major] Cisplatin / therapeutic use. Cyclooxygenase 2 / genetics. RNA Interference. RNA, Small Interfering / genetics. Stomach Neoplasms / pathology
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Cell Division / drug effects. Cell Line, Tumor. Gene Expression Regulation, Enzymologic / drug effects. Gene Expression Regulation, Neoplastic / drug effects. Humans. Plasmids. RNA, Messenger / genetics

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17982644.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / RNA, Messenger; 0 / RNA, Small Interfering; EC 1.14.99.1 / Cyclooxygenase 2; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


12. Kodera Y, Ito S, Fujiwara M, Mochizuki Y, Ohashi N, Ito Y, Nakayama G, Koike M, Yamamura Y, Nakao A: In vitro chemosensitivity test to predict chemosensitivity for paclitaxel, using human gastric carcinoma tissues. Int J Clin Oncol; 2006 Dec;11(6):449-53
Hazardous Substances Data Bank. TAXOL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] In vitro chemosensitivity test to predict chemosensitivity for paclitaxel, using human gastric carcinoma tissues.
  • BACKGROUND: Therapy guided by chemotherapy sensitivity and resistance assays may lead to rational treatment decisions.
  • Paclitaxel, one of several new drugs for gastric carcinoma, has not been extensively evaluated by in vitro chemosensitivity tests.
  • METHODS: Chemosensitivity testing by histoculture drug response assay (HDRA) was performed with fresh specimens of primary tumor from 113 patients with gastric carcinoma.
  • The test was performed in medium containing paclitaxel at three different concentrations for the initial 45 samples.
  • HDRA was successfully performed for 100 of 113 samples and chemosensitivity, calculated as the percentage of optical density of a tumor treated with anticancer drugs in relation to the optical density of the tumor cultured in the medium only, was distributed widely at this concentration.
  • No significant correlation was observed between chemosensitivity and age, sex, clinical stage, histopathologic type, and outcome of patients with gastric carcinoma.
  • CONCLUSION: A histoculture drug response assay can now be performed to predict the chemosensitivity of paclitaxel at the concentration found in the current study.
  • [MeSH-major] Antineoplastic Agents, Phytogenic / therapeutic use. Drug Resistance, Neoplasm. Paclitaxel / therapeutic use. Stomach Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cell Culture Techniques. Drug Screening Assays, Antitumor. Female. Humans. Male. Middle Aged. Predictive Value of Tests. Sensitivity and Specificity. Tumor Cells, Cultured

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2006 Jan 10;24(2):259-67 [16344314.001]
  • [Cites] Surg Today. 2002;32(6):477-81 [12107769.001]
  • [Cites] Anticancer Res. 1999 Sep-Oct;19(5C):4581-6 [10650814.001]
  • [Cites] J Clin Oncol. 2003 Jun 15;21(12):2282-7 [12805327.001]
  • [Cites] Gastric Cancer. 2002;5(2):90-5 [12111584.001]
  • [Cites] Int J Oncol. 2005 Sep;27(3):637-44 [16077911.001]
  • [Cites] Jpn J Clin Oncol. 2005 Nov;35(11):672-5 [16275676.001]
  • [Cites] Methods Mol Med. 2005;110:59-67 [15901927.001]
  • [Cites] Cancer Sci. 2003 Jan;94(1):112-8 [12708484.001]
  • [Cites] Gastric Cancer. 1998 Dec;1(1):10-24 [11957040.001]
  • [Cites] Br J Cancer. 2001 Apr 6;84(7):878-80 [11286464.001]
  • [Cites] J Clin Oncol. 2005 Jan 20;23(3):422-31 [15659489.001]
  • [Cites] Eur J Cancer. 1998 Oct;34(11):1715-20 [9893658.001]
  • [Cites] Anticancer Res. 2003 Jul-Aug;23 (4):3147-50 [12926047.001]
  • [Cites] J Clin Oncol. 2004 Sep 1;22(17):3618-30 [15289487.001]
  • [Cites] N Engl J Med. 2001 Sep 6;345(10):725-30 [11547741.001]
  • [Cites] Lancet. 1999 Jul 24;354(9175):273-7 [10440302.001]
  • [Cites] Cancer Res. 1988 Jul 15;48(14):4093-100 [2898289.001]
  • [Cites] N Engl J Med. 2006 Jul 6;355(1):11-20 [16822992.001]
  • [Cites] J Clin Oncol. 1999 Dec;17(12):3810-5 [10577853.001]
  • (PMID = 17180513.001).
  • [ISSN] 1341-9625
  • [Journal-full-title] International journal of clinical oncology
  • [ISO-abbreviation] Int. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


13. Minagawa A, Otani Y, Kubota T, Wada N, Furukawa T, Kumai K, Kameyama K, Okada Y, Fujii M, Yano M, Sato T, Ito A, Kitajima M: The citrus flavonoid, nobiletin, inhibits peritoneal dissemination of human gastric carcinoma in SCID mice. Jpn J Cancer Res; 2001 Dec;92(12):1322-8
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The citrus flavonoid, nobiletin, inhibits peritoneal dissemination of human gastric carcinoma in SCID mice.
  • The enzymatic activity of MMP-9 expressed in culture medium obtained from a co-culture of TMK-1 and mouse fibroblastic cells was inhibited by nobiletin in a concentration-dependent manner.
  • These results suggest that nobiletin may be a candidate anti-metastatic drug for prevention of peritoneal dissemination of gastric cancer.
  • [MeSH-major] Citrus / chemistry. Flavones. Flavonoids / therapeutic use. Peritoneal Neoplasms / drug therapy. Peritoneal Neoplasms / secondary. Stomach Neoplasms / drug therapy. Stomach Neoplasms / pathology
  • [MeSH-minor] Animals. Body Weight / drug effects. Cell Division / drug effects. Dose-Response Relationship, Drug. Humans. Matrix Metalloproteinases / metabolism. Mice. Mice, SCID. Neoplasm Transplantation. Organ Size / drug effects. Organ Specificity. Tumor Cells, Cultured

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11749698.001).
  • [ISSN] 0910-5050
  • [Journal-full-title] Japanese journal of cancer research : Gann
  • [ISO-abbreviation] Jpn. J. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Flavones; 0 / Flavonoids; D65ILJ7WLY / nobiletin; EC 3.4.24.- / Matrix Metalloproteinases
  •  go-up   go-down


14. Kobayashi K, Yokote T, Akioka T, Hara S, Oka S, Hirata Y, Miyoshi T, Tsuji M, Hanafusa T: [Primary gastric T-cell lymphoma with predominant bone marrow infiltration undergoing aggressive clinical course]. Gan To Kagaku Ryoho; 2007 Apr;34(4):647-51
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Primary gastric T-cell lymphoma with predominant bone marrow infiltration undergoing aggressive clinical course].
  • Upper gastroduodenal endoscopy revealed a gastric tumor in the greater curvature of the body.
  • Biopsy specimens showed the infiltration of medium-sized abnormal cells.
  • Bone marrow biopsy also indicated infiltration of the medium-sized abnormal cells.
  • The diagnosis was HTLV-1 unassociated primary gastric T-cell lymphoma with bone marrow infiltration.
  • After undergoing oral chemotherapy with VP-16 at 25 mg/day, combination chemotherapy was initiated with vincristine 2 mg/day and dexamethasone 48 mg/day.
  • The man died with the aggressive clinical course after combination chemotherapy.

  • Genetic Alliance. consumer health - Gastric Lymphoma.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17431359.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antigens, CD20; 0 / Antigens, CD3
  •  go-up   go-down


15. Yeo M, Kim DK, Park HJ, Cho SW, Cheong JY, Lee KJ: Blockage of intracellular proton extrusion with proton extrusions with proton pump inhibitor induces apoptosis in gastric cancer. Cancer Sci; 2008 Jan;99(1):185
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Blockage of intracellular proton extrusion with proton extrusions with proton pump inhibitor induces apoptosis in gastric cancer.
  • Proton pump inhibitors have been used for treatment of acid-related gastroesophageal diseases and they act as potent inhibitors of gastric acid pump, H(+)/K(+)-ATPase.
  • In this study, we evaluated whether blocking of proton extrusion with proton pump inhibitors could inhibit the viability of gastric cancer cells.
  • Treatment of human gastric cancer cells with proton pump inhibitors significantly attenuated cell viability in a time- and dose-dependent manner.
  • Gastric cancer cells showed the resistance to acidity of culture medium, which was related with a remarkable increase of extracellular signal-regulated protein kinase 1/2 (ERK1/2) phosphorylation in the acidic condition.
  • This ERK1/2 phosphorylation was completely inhibited by pretreatment with proton pump inhibitors, suggesting that its inhibitory action on phosphorylation of ERK1/2 might contribute to the induction of apoptosis in gastric cancer cells.
  • In conclusion, our results suggest novel therapeutic approaches for gastric cancer with proton pump inhibitors.
  • [MeSH-major] 2-Pyridinylmethylsulfinylbenzimidazoles / pharmacology. Apoptosis / drug effects. Omeprazole / pharmacology. Proton Pump Inhibitors / pharmacology. Stomach Neoplasms / drug therapy
  • [MeSH-minor] Caspases / metabolism. Cell Line, Tumor. Culture Media. Enzyme Activation / drug effects. Humans. Hydrogen-Ion Concentration. Mitochondria / drug effects. Mitochondria / physiology. Mitogen-Activated Protein Kinase 1 / antagonists & inhibitors. Mitogen-Activated Protein Kinase 1 / metabolism. Mitogen-Activated Protein Kinase 3 / antagonists & inhibitors. Mitogen-Activated Protein Kinase 3 / metabolism. Phosphorylation / drug effects

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. PANTOPRAZOLE .
  • Hazardous Substances Data Bank. OMEPRAZOLE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [RetractionIn] Yeo M, Kim DK, Park HJ, Cho SW, Cheong JY, Lee KJ. Cancer Sci. 2008 Jan;99(1):185 [17956591.001]
  • (PMID = 18224727.001).
  • [ISSN] 1349-7006
  • [Journal-full-title] Cancer science
  • [ISO-abbreviation] Cancer Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Retracted Publication
  • [Publication-country] England
  • [Chemical-registry-number] 0 / 2-Pyridinylmethylsulfinylbenzimidazoles; 0 / Culture Media; 0 / Proton Pump Inhibitors; D8TST4O562 / pantoprazole; EC 2.7.11.24 / Mitogen-Activated Protein Kinase 1; EC 2.7.11.24 / Mitogen-Activated Protein Kinase 3; EC 3.4.22.- / Caspases; KG60484QX9 / Omeprazole
  •  go-up   go-down


16. Oshima T, Imada T, Nagashima Y, Cho H, Shiozawa M, Rino Y, Takanashi Y: Role of nitric oxide in human gastric cancer cells treated with 5-fluorouracil. Oncol Rep; 2001 Jul-Aug;8(4):847-9
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Role of nitric oxide in human gastric cancer cells treated with 5-fluorouracil.
  • We examined whether 5-fluorouracil (5-FU) induces nitric oxide (NO) production and evaluated the role of NO in antitumor activity in human gastric cancer cells.
  • MKN-1 gastric cancer cells were treated with the IC50 of 5-FU in the presence of interferon-gamma (IFN-gamma).
  • In addition, s-methylisothiourea (an antagonist of inducible nitric oxide synthase) or anti-TNF-alpha antibody was added to the culture medium.
  • After 5-FU treatment in the presence of IFN-gamma, NO and TNF-alpha were produced and anti-tumor activity was enhanced.
  • In contrast, s-methylisothiourea abolished the antitumor activity of 5-FU treatment.
  • 5-FU induces NO production by gastric cancer cells, and NO participates in antitumor activity in gastric cancer cells.
  • [MeSH-major] Antimetabolites, Antineoplastic / pharmacology. Fluorouracil / pharmacology. Nitric Oxide / biosynthesis. Stomach Neoplasms / drug therapy. Tumor Cells, Cultured / drug effects
  • [MeSH-minor] Enzyme Inhibitors / pharmacology. Enzyme-Linked Immunosorbent Assay. Formazans. Humans. Interferon-gamma / pharmacology. Isothiuronium / analogs & derivatives. Isothiuronium / pharmacology. Nitric Oxide Synthase / antagonists & inhibitors. Nitric Oxide Synthase / metabolism. Nitric Oxide Synthase Type II. Tetrazolium Salts. Tumor Necrosis Factor-alpha / biosynthesis

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. NITRIC OXIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11410796.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Enzyme Inhibitors; 0 / Formazans; 0 / Tetrazolium Salts; 0 / Tumor Necrosis Factor-alpha; 22584-04-9 / Isothiuronium; 23305-68-2 / MTT formazan; 2986-19-8 / S-methylisothiopseudouronium; 31C4KY9ESH / Nitric Oxide; 82115-62-6 / Interferon-gamma; EC 1.14.13.39 / NOS2 protein, human; EC 1.14.13.39 / Nitric Oxide Synthase; EC 1.14.13.39 / Nitric Oxide Synthase Type II; U3P01618RT / Fluorouracil
  •  go-up   go-down


17. Ohi S, Hashimoto H, Tachibana T, Tabei I, Nakajima M, Sato K, Yanaga K, Ishikawa H: Establishment and characterization of EB virus-free normal B-lymphocyte and interleukin-6-producing poorly differentiated adenocarcinoma cell lines derived from gastric tumor tissue. Hum Cell; 2005 Mar;18(1):35-44
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Establishment and characterization of EB virus-free normal B-lymphocyte and interleukin-6-producing poorly differentiated adenocarcinoma cell lines derived from gastric tumor tissue.
  • The tumor delivered to our laboratory from an operating room was cut into small pieces and cultured on the dishes.
  • Injection of HIGS-BL cells, other B-lymphocyte cell lines, or the conditioned media of HIGS-BL cells into nude mice bearing HIGS-grafted tumors was performed individually.
  • The inhibition of grafted tumor growth was confirmed by the injection of not only the HIGS-BL cells but also the B-lymphocytes.
  • Furthermore, this inhibition was only observed when the conditioned medium of B-lymphocytes was injected into the nude mice.
  • In addition, susceptibility tests to anti-cancer drugs suggested that HIGS cells were sensitive to CDDP, ADM and MMC, and HIGS-BL cells were sensitive to CDDP.
  • If CDDP was used for chemotherapy in the patient, the drug produced atrophy of HIGS-BL cells.
  • The study about HIGS and HIGS-BL cells reported the necessity for novel therapeutic approaches in oncotherapy.
  • [MeSH-minor] Animals. Antineoplastic Agents / pharmacology. Cells, Cultured. Cisplatin / pharmacology. Culture Media, Conditioned / pharmacology. Drug Screening Assays, Antitumor. Herpesvirus 4, Human. Humans. Karyotyping. Male. Mice. Mice, Nude. Neoplasm Transplantation

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Pathol. 1993 Nov;143(5):1250-4 [8238241.001]
  • [Cites] Cancer Immunol Immunother. 2004 Sep;53(9):786-92 [15185009.001]
  • [Cites] Hum Cell. 1999 Mar;12(1):3-10 [10457900.001]
  • [Cites] Cancer Res. 1993 Sep 15;53(18):4175-81 [8364912.001]
  • [Cites] Microbes Infect. 2000 Feb;2(2):115-20 [10742683.001]
  • [Cites] FEBS Lett. 1989 Jul 3;250(2):607-10 [2787758.001]
  • [Cites] Cancer Res. 1990 Nov 1;50(21):6959-65 [2208162.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 Sep 13;91(19):9131-5 [8090780.001]
  • (PMID = 16130898.001).
  • [ISSN] 0914-7470
  • [Journal-full-title] Human cell
  • [ISO-abbreviation] Hum. Cell
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Culture Media, Conditioned; 0 / Interleukin-6; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


18. Yabuki K, Tamasaki Y, Satoh K, Maekawa T, Matsumoto M: Primary gastric lymphoma with spontaneous perforation: report of a case. Surg Today; 2000;30(11):1030-3
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary gastric lymphoma with spontaneous perforation: report of a case.
  • Primary gastric lymphoma with spontaneous perforation is rare.
  • Emergency endoscopic examination showed a perforated gastric tumor in the lower body of the greater curvature, and a distal subtotal gastrectomy with lymph node dissection was performed.
  • The resected tumor measured 10.0 x 8.0 cm and was associated with an area of ulceration, 8.0 x 6.0 cm in size, and perforation, 1.0 x 0.5 cm in size.
  • Pathological examination confirmed a diagnosis of B-cell malignant lymphoma of the diffuse, medium-sized cell type.
  • Postoperative adjuvant chemotherapy comprising cyclophosphamide, doxorubicin, vincristine, and prednisolone (CHOP) was given.
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols. Chemotherapy, Adjuvant. Cyclophosphamide. Doxorubicin. Humans. Male. Middle Aged. Prednisone. Rupture, Spontaneous. Vincristine

  • Genetic Alliance. consumer health - Gastric Lymphoma.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11110402.001).
  • [ISSN] 0941-1291
  • [Journal-full-title] Surgery today
  • [ISO-abbreviation] Surg. Today
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] JAPAN
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


19. Raderer M, Püspök A, Birkner T, Streubel B, Chott A: Primary gastric mantle cell lymphoma in a patient with long standing history of Crohn's disease. Leuk Lymphoma; 2004 Jul;45(7):1459-62
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary gastric mantle cell lymphoma in a patient with long standing history of Crohn's disease.
  • Virtually all cases are of B-cell lineage, including extranodal marginal zone B-cell lymphomas of mucosa-associated lymphoid tissue (MALT lymphoma) and diffuse large B-cell lymphomas.
  • While secondary gastric involvement from nodal mantle cell lymphoma (MCL) or in the course of primary intestinal MCL (lymphomatous polyposis) have been described, primary gastric MCL has not been reported so far.
  • A 74-year-old man with a 14 year-history of Crohn's disease was admitted at a general hospital due to epigastric pain refractory to therapy with proton-pump inhibitors.
  • Endoscopy disclosed a large polypoid tumor with an ulcerated surface at the greater curvature of the gastric antrum.
  • Endosonography demonstrated the tumor to be limited to the stomach with only local lymph node involvement.
  • Histology of gastric biopsies revealed a dense atypical lymphoid infiltrate composed of small to medium sized cells with slightly irregular nuclear contours.
  • Following chemotherapy the patient is disease free at 24 months after diagnosis.
  • This is the first case of a primary localized gastric MCL.
  • [MeSH-minor] Aged. Antibodies, Monoclonal / therapeutic use. Antibodies, Monoclonal, Murine-Derived. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biopsy. Cyclophosphamide / administration & dosage. Diagnosis, Differential. Disease Susceptibility. Doxorubicin / administration & dosage. Humans. Immunophenotyping. Lymphoma, B-Cell, Marginal Zone / diagnosis. Male. Prednisone / administration & dosage. Remission Induction. Rituximab. Vincristine / administration & dosage


20. Li QM, Kan FJ, Min CY: Effect of Weikangning on gastric cancer cell growth and expression of vascular endothelial growth factor and its receptors KDR and Flt-1. World J Gastroenterol; 2005 Feb 21;11(7):938-42
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effect of Weikangning on gastric cancer cell growth and expression of vascular endothelial growth factor and its receptors KDR and Flt-1.
  • AIM: To observe the effect of Chinese traditional herbal decoction Weikang-ning (WKN) on cell growth and expression of VEGF and its receptors KDR and Flt-1 in gastric cancer cell line MGC-803.
  • METHODS: A total of 120 male Wistar rats were divided into control group, high dose, medium dose and low dose groups fed with natural saline, 20, 10, and 5 g/kg of WKN, respectively.
  • The experimental animals were finally killed for the preparation of drug-containing serum.
  • The gastric cancer cell MGC-803 was cultured with the drug-containing serum drawn from the rats in different groups.
  • RESULTS: The proportion of cells in G(0)-G(1) phase was (65.40+/-0.41)%, (56.92+/-0.62)%, (55.89+/-0.69)% in high, medium and low dose groups respectively vs (41.35+/-0.55)% in control group (P<0.01), while the cells in G(2)-S and S phases were (11.62+/-0.62)% and (22.99+/-0.69)%, (17.08+/-0.80)% and (26.00+/-0.71)%, (19.37+/-0.57)% and (24.74+/-0.64)% in high, medium and low dose groups, respectively, vs (23.65+/-0.56)% and (35.00+/-0.60)% in control group (P<0.01).
  • CONCLUSION: The decoction of WKN suppresses the growth of gastric cancer cell MGC-803 and decreases the expression of mRNA of both VEGF and its receptors KDR and Flt-1.
  • [MeSH-major] Drugs, Chinese Herbal / pharmacology. Stomach Neoplasms / drug therapy. Vascular Endothelial Growth Factor A / genetics. Vascular Endothelial Growth Factor Receptor-1 / genetics. Vascular Endothelial Growth Factor Receptor-2 / genetics
  • [MeSH-minor] Animals. Cell Division / drug effects. Cell Line, Tumor. Gene Expression Regulation, Neoplastic / drug effects. RNA, Messenger / analysis. Rats. Rats, Wistar

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15742392.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Drugs, Chinese Herbal; 0 / RNA, Messenger; 0 / Vascular Endothelial Growth Factor A; EC 2.7.10.1 / Vascular Endothelial Growth Factor Receptor-1; EC 2.7.10.1 / Vascular Endothelial Growth Factor Receptor-2
  • [Other-IDs] NLM/ PMC4250781
  •  go-up   go-down


21. Ohmiya N, Emi N, Niwa Y, Goto H, Hayakawa T: Insulin-enhanced liposome-mediated gene transfer into a gastric carcinoma cell line. Clin Exp Pharmacol Physiol; 2002 Jul;29(7):544-8
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Insulin-enhanced liposome-mediated gene transfer into a gastric carcinoma cell line.
  • 2. To assess the effect of insulin on lipofection efficiency and the cell cycle, expression of green fluorescent protein (GFP) and DNA distribution in gastric (MKN1), colonic (HT29) and pancreatic (BxPC3) carcinoma cell lines was analysed using flow cytometry.
  • 3. The percentage of positive cells with GFP was significantly higher in MKN1 cells in culture medium with 5 mg/mL insulin than without insulin, whereas the percentage was the same in HT29 and BxPC3 cells with insulin as without insulin.
  • [MeSH-major] Cell Cycle / drug effects. Insulin / pharmacology. Stomach Neoplasms / genetics. Transfection
  • [MeSH-minor] Colonic Neoplasms / genetics. Colonic Neoplasms / pathology. Colonic Neoplasms / therapy. Culture Media. Flow Cytometry. Gene Expression. Genetic Therapy. Green Fluorescent Proteins. Humans. Liposomes. Luminescent Proteins / genetics. Microscopy, Confocal. Pancreatic Neoplasms / genetics. Pancreatic Neoplasms / pathology. Pancreatic Neoplasms / therapy. Tumor Cells, Cultured

  • MedlinePlus Health Information. consumer health - Diabetes Medicines.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12060095.001).
  • [ISSN] 0305-1870
  • [Journal-full-title] Clinical and experimental pharmacology & physiology
  • [ISO-abbreviation] Clin. Exp. Pharmacol. Physiol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Culture Media; 0 / Insulin; 0 / Liposomes; 0 / Luminescent Proteins; 147336-22-9 / Green Fluorescent Proteins
  •  go-up   go-down


22. Kubisch CH, Beigel F, Ihrler S, Goke B, Reiser MF, Hoffmann RT: Oesophageal ulceration after selective internal radiation therapy in a patient with carcinoma of unknown primary. Z Gastroenterol; 2010 May;48(5):546-50
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Oesophageal ulceration after selective internal radiation therapy in a patient with carcinoma of unknown primary.
  • BACKGROUND: Cancer of unknown primary (CUP) is defined as histologically confirmed metastases in the absence of an identifiable primary tumor.
  • The medium survival averages 6 to 9 months.
  • After cycles of chemotherapy and hemihepatectomy the tumor returned and showed hepatic progression.
  • The patient was evaluated for selective internal radiation therapy (SIRT).
  • This side effect appears in up to 12 % of patients, often very late after treatment, is refractory to pharmacotherapy and persistent over a long time.
  • CONCLUSIONS: SIRT is a new, effective treatment in patients with hepatic CUP.
  • Because of the anticipated increase of this therapy, adverse side effects such as ulcerations in the upper-GI tract secondary to ectopic implantation of microspheres may be seen more commonly.
  • [MeSH-major] Adenocarcinoma / radiotherapy. Adenocarcinoma / secondary. Brachytherapy / adverse effects. Duodenal Ulcer / pathology. Embolization, Therapeutic. Esophageal Diseases / pathology. Esophagus / radiation effects. Liver Neoplasms / radiotherapy. Liver Neoplasms / secondary. Neoplasms, Unknown Primary / radiotherapy. Radiation Injuries / pathology. Stomach Ulcer / pathology. Ulcer / pathology
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Disease Progression. Duodenum / pathology. Duodenum / radiation effects. Endoscopy, Digestive System. Female. Gastric Mucosa / pathology. Gastric Mucosa / radiation effects. Hepatectomy. Humans. Intestinal Mucosa / pathology. Intestinal Mucosa / radiation effects. Microspheres. Middle Aged. Neoadjuvant Therapy. Radiotherapy, Adjuvant

  • MedlinePlus Health Information. consumer health - Esophagus Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20449787.001).
  • [ISSN] 1439-7803
  • [Journal-full-title] Zeitschrift für Gastroenterologie
  • [ISO-abbreviation] Z Gastroenterol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


23. Mizumura Y, Matsumura Y, Hamaguchi T, Nishiyama N, Kataoka K, Kawaguchi T, Hrushesky WJ, Moriyasu F, Kakizoe T: Cisplatin-incorporated polymeric micelles eliminate nephrotoxicity, while maintaining antitumor activity. Jpn J Cancer Res; 2001 Mar;92(3):328-36
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The polymeric drug thus obtained was observed to form a micelle structure in aqueous medium, showing excellent water solubility.
  • In the present study, in vitro and in vivo antitumor activity against several human tumor cell lines, toxicity and pharmacokinetic characteristics in rodents of CDDP-incorporated polymeric micelles (CDDP / m) were evaluated in comparison with those of CDDP.
  • In vitro, CDDP / m exhibited 10 - 17% of the cytotoxicity of CDDP against human tumor cell lines.
  • In vivo CDDP / m treatment resulted in higher and more sustained levels in tumor tissue than CDDP, and showed similar antitumor activity to CDDP against MKN 45 human gastric cancer xenograft.
  • CDDP / m treatment caused much less renal damage than CDDP.
  • These results indicate that CDDP / m treatment can reduce CDDP-induced nephrotoxicity without compromising the anticancer cytotoxicity of CDDP.
  • [MeSH-major] Aspartic Acid / pharmacokinetics. Aspartic Acid / therapeutic use. Cell Survival / drug effects. Cisplatin / pharmacokinetics. Cisplatin / therapeutic use. Kidney / drug effects. Lung Neoplasms / drug therapy. Polyethylene Glycols / pharmacokinetics. Polyethylene Glycols / therapeutic use. Stomach Neoplasms / drug therapy
  • [MeSH-minor] Animals. Breast Neoplasms. Colonic Neoplasms. Drug Carriers. Female. Humans. Male. Mice. Mice, Inbred C57BL. Mice, Nude. Micelles. Tissue Distribution. Transplantation, Heterologous. Tumor Cells, Cultured

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. (L)-ASPARTIC ACID .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11267944.001).
  • [ISSN] 0910-5050
  • [Journal-full-title] Japanese journal of cancer research : Gann
  • [ISO-abbreviation] Jpn. J. Cancer Res.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Drug Carriers; 0 / Micelles; 0 / poly(ethylene glycol)-poly(cisplatin-aspartic acid); 30IQX730WE / Polyethylene Glycols; 30KYC7MIAI / Aspartic Acid; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


24. Li F, Weng Y, Wang L, He H, Yang J, Tang X: The efficacy and safety of bufadienolides-loaded nanostructured lipid carriers. Int J Pharm; 2010 Jun 30;393(1-2):203-11
Hazardous Substances Data Bank. DEOXYCHOLIC ACID .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Bufadienolides-loaded nanostructured lipid carriers (BU-NLC) were prepared for parenteral application using glyceryl monostearate as solid core, medium-chain triglyceride and oleic acid as liquid lipid material, and Lipoid E-80, sodium deoxycholate and pluronic F68 as stabilizers.
  • Against human astrocytoma cell line (U87-MG) and human gastric carcinoma cell line (HGC-27) BU-NLC exhibited cytotoxicity that was similar to that of the free drug, and superior to that of the commercially available fluorouracil injection.
  • A sarcoma-180 tumor model further confirmed the advantages of BU-NLC versus BU-S.
  • [MeSH-major] Antineoplastic Agents / pharmacology. Bufanolides / pharmacology. Drug Carriers. Lipids / chemistry. Nanostructures. Sarcoma 180 / drug therapy
  • [MeSH-minor] Animals. Cell Line, Tumor. Cell Proliferation / drug effects. Chemistry, Pharmaceutical. Deoxycholic Acid / chemistry. Dose-Response Relationship, Drug. Drug Compounding. Excipients / chemistry. Female. Glycerides / chemistry. Hemolysis / drug effects. Humans. Inhibitory Concentration 50. Injections, Intravenous. Lethal Dose 50. Male. Mice. Oleic Acid / chemistry. Poloxamer / chemistry. Rabbits. Rats. Rats, Wistar. Technology, Pharmaceutical / methods. Tissue Distribution. Triglycerides / chemistry

  • Hazardous Substances Data Bank. OLEIC ACID .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2010 Elsevier B.V. All rights reserved.
  • (PMID = 20385221.001).
  • [ISSN] 1873-3476
  • [Journal-full-title] International journal of pharmaceutics
  • [ISO-abbreviation] Int J Pharm
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Bufanolides; 0 / Drug Carriers; 0 / Excipients; 0 / Glycerides; 0 / Lipids; 0 / Triglycerides; 005990WHZZ / Deoxycholic Acid; 106392-12-5 / Poloxamer; 2UMI9U37CP / Oleic Acid; 31566-31-1 / glyceryl monostearate
  •  go-up   go-down


25. Nakamura M, Fujishima S, Hori S, Nakamura H, Namiki M, Takahashi M, Yamaguchi K: [An adult case of cervico-mediastinal tuberculous lymphadenitis]. Nihon Kokyuki Gakkai Zasshi; 2000 Mar;38(3):223-8
MedlinePlus Health Information. consumer health - Lung Diseases.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • On admission, a right cervical tumor was palpable and chest X-ray films revealed widened superior mediastinum.
  • Chest computed tomography showed multiple swollen mediastinal lymph nodes, including multiple low-density areas and contrast medium-enhanced septa and margins.
  • A PPD skin test was strongly positive and ribosomal RNA of tubercle bacilli was detected in aspirated gastric juice.
  • Although anti-tuberculous chemotherapy was initiated, fever and cough persisted, and hoarseness due to left recurrent laryngeal nerve palsy developed.
  • After 9 months of extended anti-tuberculous chemotherapy, the cervical and mediastinal masses receded and the abnormal chest X-ray shadows disappeared.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10846406.001).
  • [ISSN] 1343-3490
  • [Journal-full-title] Nihon Kokyūki Gakkai zasshi = the journal of the Japanese Respiratory Society
  • [ISO-abbreviation] Nihon Kokyuki Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] JAPAN
  •  go-up   go-down


26. Kunisaki Y, Muta T, Yamano Y, Kobayashi Y: Detection of two cell populations corresponding to distinct maturation stages in API-2/MLT-positive mucosa-associated lymphoid tissue lymphoma cells proliferating in pleural effusion. Int J Hematol; 2003 Nov;78(4):357-61

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Detection of two cell populations corresponding to distinct maturation stages in API-2/MLT-positive mucosa-associated lymphoid tissue lymphoma cells proliferating in pleural effusion.
  • A 66-year-old man was admitted to our hospital because of an intra-abdominal tumor and pleural effusion (PE).
  • Computed tomography scans showed extensive thickening of the gastric wall and bilateral massive PE without lymph node or pulmonary involvement.
  • A histologic examination of the gastric mucosa showed a diffuse infiltration of small- to medium-sized lymphoid CD20-bearing cells, some of which showed a plasmacytoid morphology.
  • The diagnosis was gastric mucosa-associated lymphoid tissue (MALT) lymphoma infiltrating to the PE, PB, and BM.
  • The patient had a good response to fludarabine treatment, which was followed with rituximab therapy.
  • In general, gastric MALT lymphoma cells have a tendency to differentiate into plasma cells.
  • [MeSH-minor] Aged. Antigens, Differentiation, B-Lymphocyte / analysis. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. B-Lymphocytes / pathology. Cell Adhesion Molecules / analysis. Cell Differentiation. Cell Division. Humans. Immunophenotyping. Male. Neoplasm, Residual. Stomach Neoplasms / diagnosis. Stomach Neoplasms / drug therapy. Stomach Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 1997 Sep 15;57(18):3944-8 [9307277.001]
  • [Cites] Blood. 2002 Jan 1;99(1):3-9 [11756145.001]
  • [Cites] Blood. 1994 Sep 1;84(5):1361-92 [8068936.001]
  • [Cites] Lancet. 1991 Nov 9;338(8776):1175-6 [1682595.001]
  • [Cites] Am J Pathol. 1999 Dec;155(6):2019-27 [10595932.001]
  • [Cites] Mod Pathol. 2001 Aug;14(8):798-805 [11504840.001]
  • [Cites] Int J Hematol. 2002 Dec;76(5):385-93 [12512832.001]
  • [Cites] Blood. 2000 Jul 15;96(2):410-9 [10887100.001]
  • [Cites] Rinsho Ketsueki. 2000 Nov;41(11):1183-8 [11193437.001]
  • [Cites] Br J Haematol. 2001 Dec;115(3):588-94 [11736940.001]
  • [Cites] Semin Oncol. 2002 Feb;29(1 Suppl 2):36-40 [11842387.001]
  • [Cites] Am J Clin Pathol. 2001 Nov;116(5):683-90 [11710684.001]
  • [Cites] Gut. 2001 Oct;49(4):519-25 [11559649.001]
  • [Cites] Am J Clin Pathol. 1999 Jan;111(1 Suppl 1):S8-12 [9894466.001]
  • [Cites] Am J Pathol. 1997 May;150(5):1583-93 [9137085.001]
  • [Cites] Br J Haematol. 1997 Jun;97(3):515-22 [9207392.001]
  • [Cites] Jpn J Cancer Res. 2000 Mar;91(3):301-9 [10760689.001]
  • [Cites] Leuk Res. 1990;14(7):617-22 [2388473.001]
  • [Cites] Acta Otolaryngol Suppl. 1996;523:259-62 [9082801.001]
  • [Cites] Cancer Genet Cytogenet. 2000 Mar;117(2):113-7 [10704680.001]
  • [Cites] Cell. 1993 Jul 16;74(1):185-95 [7687523.001]
  • (PMID = 14686495.001).
  • [ISSN] 0925-5710
  • [Journal-full-title] International journal of hematology
  • [ISO-abbreviation] Int. J. Hematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / API2-MALT1 fusion protein, human; 0 / Antigens, Differentiation, B-Lymphocyte; 0 / Cell Adhesion Molecules; 0 / Oncogene Proteins, Fusion
  •  go-up   go-down


27. Jiang R, Kanamori M, Satoh Y, Fukuda M, Ikuta K, Murakami M, Sairenji T: Contrasting effects of hydroxyurea on cell growth and reduction in Epstein-Barr virus genomes in EBV-infected epithelioid cell lines vs Burkitt's lymphoma cell lines. J Med Virol; 2003 Jun;70(2):244-52
Hazardous Substances Data Bank. HYDROXYUREA .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Eliminating Epstein-Barr virus (EBV) genomes from infected cells is an intriguing theoretical strategy in therapy for EBV-associated malignant diseases.
  • Respective patterns were characterized for hydroxyurea (HU)-promoted loss of EBV genomes from EBV-infected epithelioid cell lines derived from the noncancerous portion of gastric carcinoma tissues and Burkitt's lymphoma (BL) cell lines.
  • On passage in medium with 50 microM HU, the fraction of EBV nuclear antigen (EBNA)-positive cells was reduced substantially in the BL cell lines, but only slightly in the epithelioid cell lines.
  • [MeSH-major] Herpesvirus 4, Human / drug effects. Herpesvirus 4, Human / growth & development. Hydroxyurea / pharmacology
  • [MeSH-minor] Burkitt Lymphoma. Cell Cycle / drug effects. Cell Line, Transformed. DNA, Viral / analysis. Epithelioid Cells / virology. Genome, Viral. Humans. In Situ Hybridization, Fluorescence. Tumor Cells, Cultured. Virus Latency

  • Genetic Alliance. consumer health - Burkitt's Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2003 Wiley-Liss, Inc.
  • (PMID = 12696111.001).
  • [ISSN] 0146-6615
  • [Journal-full-title] Journal of medical virology
  • [ISO-abbreviation] J. Med. Virol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Viral; X6Q56QN5QC / Hydroxyurea
  •  go-up   go-down


28. Herber S, Otto G, Schneider J, Manzl N, Kummer I, Kanzler S, Schuchmann A, Thies J, Düber C, Pitton M: Transarterial chemoembolization (TACE) for inoperable intrahepatic cholangiocarcinoma. Cardiovasc Intervent Radiol; 2007 Nov-Dec;30(6):1156-65
Hazardous Substances Data Bank. MITOMYCIN C .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The aim of this retrospective study was to determine the safety and efficacy of chemoembolization (TACE) as palliative treatment for patients with unresectable intrahepatic cholangiocarcinoma (CCA) and to compare the results with those in the literature.
  • Fifteen patients with histology-proven CCA (5 men, 10 women) had received palliative treatment with TACE over a 6-year period.
  • The treatment protocol comprised repeated TACE at a minimum of 8-week intervals.
  • TACE was performed with a mixture of 10 ml Lipiodol and 10 mg mitomycin C injected into the tumor-supplying vessels.
  • Mean tumor size was 10.8 +/- 4.6 cm (range, 2.0-18.0 cm).
  • Unifocal tumor disease was diagnosed in eight patients, and multifocal disease in seven.
  • According to RECIST criteria interim best response to therapy was stable disease in 9 of 15 patients, a partial response in 1 of 15 patients, and tumor progression in 4 of 15 patients.
  • No deaths and no acute liver failure occurred under TACE therapy.
  • Major complications were observed in two patients, comprising anaphylactic shock owing to contrast medium administration in one and gastric ulceration due to lipiodol displacement in the second patient.
  • These results demonstrate that TACE is a safe procedure with a moderate number of complications for patients suffering from inoperable CCA.
  • According to recently published data on i.v. chemotherapy we suggest that TACE might be able to prolong survival in selected patients who would succumb under other palliative treatment modalities.
  • [MeSH-major] Bile Duct Neoplasms / therapy. Bile Ducts, Intrahepatic. Chemoembolization, Therapeutic / methods. Cholangiocarcinoma / therapy
  • [MeSH-minor] Aged. Aged, 80 and over. Antibiotics, Antineoplastic / administration & dosage. Contrast Media / administration & dosage. Female. Humans. Iodized Oil / administration & dosage. Iopamidol / analogs & derivatives. Male. Middle Aged. Mitomycin / administration & dosage. Statistics, Nonparametric. Survival Rate. Tomography, X-Ray Computed. Treatment Outcome

  • Genetic Alliance. consumer health - Intrahepatic cholangiocarcinoma.
  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17508242.001).
  • [ISSN] 0174-1551
  • [Journal-full-title] Cardiovascular and interventional radiology
  • [ISO-abbreviation] Cardiovasc Intervent Radiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / Contrast Media; 17E17JBP8L / iomeprol; 50SG953SK6 / Mitomycin; 8001-40-9 / Iodized Oil; JR13W81H44 / Iopamidol
  •  go-up   go-down






Advertisement